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Told through the example of South African middle-distance runner Caster Semenya, 
this discussion starter examines the controversial area of gender in sport from a 
scienti"c viewpoint. Women have been segregated from men in most sporting 
disciplines for as long as they have been permitted to compete, but seated in a society 
only just beginning to delineate the concepts of sex and gender identity, consensus 
needs to be reached on how or if we should categorise elite athletes, whilst upholding 
the integrity and fairness of competitive sport. The parameters used to sort athletes 
into today’s binary gender categories have recently come under scrutiny in the cases 
of athletes with Di!erences of Sex Development (DSD). Semenya has elevated 
serum testosterone and her eligibility to continue competing and winning with 
females has now been brought into contention by the IAAF resulting in a legal battle. 
However, the scienti"c evidence on which the IAAF ruling is based is far from robust. 
Athletics, a sport tainted by a history of doping with anabolic steroids, is "ghting 
to maintain values of fairness by aiming to govern the levels endogenous steroids 
permitted in competition. Semenya’s is a pertinent example of a wider issue which 
is of interest from a scienti"c, ethical, political, legal and social standpoint because of 
the complexity of hormone systems and the fact that circulating levels of hormone do 
not necessarily equate with actions of those hormones.  With confusing mainstream 
media coverage lacking consensus, the scienti"c community deserve clarity on the 
issue to allow us to engage in meaningful discussion and contribute to the debate.
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As the president of the International Association of Athletics 
Federations (IAAF) Lord Sebastian Coe put it: “It’s pretty straight-
forward. Athletics has two classi"cations; it has age and gender.” (1) 
However, far from straight forward is the matter of how we de"ne 
these currently binary male/female categories in sport. In light of 
the new competition eligibility regulations released by the IAAF 
in April 2018, focussed on regulating the levels of testosterone in 
female athletes with di!erences of sex development (DSD) that are 
permitted to compete, (2) the topic is more controversial than ever. 
This discussion takes place in the context of a progressive society 
with an increasing acceptance for values of feminism and gender-
equality, which is only beginning to understand the complexities of 
gender as a #uid concept. 
For the purposes of this article:
• ‘Sex’ – the biological classi"cation largely considered binary in 
terms of male/female as comprised of chromosomal, phenotypic 
and hormonal components
• ‘Gender’ – one’s own identity in relation to masculinity and 
femininity, self-de"ned and nuanced within social and cultural 
in#uences 
It is indisputable that taking performance-enhancing anabolic ster-
oids in sport is immoral and considered ‘doping’, but how do we 
manage and classify athletes, speci"cally females, who synthesise an 
excess of these steroids naturally? The issue of gender and sport has 
generated signi"cant public attention, and although caught up in le-
gal battles themselves, the individual athletes it a!ects the most have 
become involuntary "gureheads of mainstream media campaigns 
surrounding the issue. Whilst those in media and sport are quick 
to discuss the topic through the stories of these athletes, largely le$ 
out of the debate has been the scienti"c community, who could be 
instrumental in providing the biomedical expertise and objective 
oversight that this dispute necessitates.
 &"$"*Ґƒґ
Women have been segregated from men in all competitive sports 
since their inclusion has been permitted, with a few notable excep-
tions including equestrian and mixed pair events. 
Di!erences in human physiology based on sex, which give men 
a physical advantage in many competitive sports, forms the basis 
of this segregation. However, with any categorisation, a sorting 
process must occur. Physical examinations were relied upon in 
the 1960s to prevent men competing as women; these were later 
replaced by buccal smears to identify sex chromosomes – but the 
smears were considered unreliable, so the IAAF abandoned them 
in 1991. Genetic testing is also inherently #awed in some DSD ath-
letes, since XY individuals can develop female characteristics due to 
androgen insensitivity and conversely, XX individuals can develop 
male characteristics due to hyperandrogenism for a number of 
reasons – congenital adrenal hyperplasia, for example, where there 
is an excess of androgen because of a genetic biochemical aberration 
in steroid hormone. 
Currently, there are no IAAF rules to endorse standard sex testing, 
since men attempting to compete as women would presumably 
be identi"ed in anti-doping urine tests. However, any athlete can 
be asked in front of a medical panel including an endocrinologist, 
a psychologist and a gynaecologist should their sex be challenged. 
Since androgens are responsible for the development of many of the 
advantage-conferring male characteristics in either sex, testosterone 
is the IAAF’s chosen route on which to base their regulation. Such 
a binary classi"cation system inevitably runs into trouble when it 
invites a global population which doesn’t "t neatly into two catego-
ries to compete. Does such a system become discriminatory when 
it doesn’t include transgender and intersex members of society, or 
subjects them to rigorous medical testing that other athletes would 
not be subject to?
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Summarised in Box 1 are the current IAAF regulations as released 
in April 2018 and re"ned in 2019, stating that DSD female athletes 
are only permitted to compete in competitive sport with medical 
intervention. It is important to understand the historical context 
which shaped these regulations. First mention of ‘Hyperandro-
genism Regulations’ by the IAAF was in May 2011 following the 
emergence of Caster Semenya at the 2009 Athletics world champi-
onships in Berlin, winning the 800m gold at the age of 18. (4) The 
regulations stated that any athlete, female in law, with hyperandro-
genism would only be permitted to compete if their testosterone 
was below the ‘male range’ de"ned as <10 nmol/L or within the 
‘male range’ and have an “androgen resistance such that she derives 
no competitive advantage”. (5)
2015 saw the landmark case of Dutee Chand, a hyperandrogenic 
female Indian athlete who was one of the "rst from her country to 
reach a global sprinting "nal in 2013, get caught in a legal dispute 
against the IAAF and her home institution of the Athletics Federa-
tion of India who demanded she take a gender test a$er her elevat-
ed serum testosterone was discovered. (6) Chand won her appeal 
on the grounds of the IAAF providing the panel with insu%cient 
scienti"c evidence to support their 2011 hyperandrogenism regula-
tions – speci"cally the exact degree of advantage which testosterone 
gave hyperandrogenic female athletes. The Court of Arbitration for 
Sport therefore suspended the ‘Hyperandrogenism Regulations’ 
for a period of two years during which the IAAF was expected to 
provide written evidence to support them, leaving Chand free to 
resume competing. “I am who I am” she stated at the time. (6,7)
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During that two years (which was eventually extended to three) 
the IAAF commissioned two scienti"c papers to provide a founda-
tion for their revised and most recent regulations on DSD athletes 
as summarised below. (8,9) The integrity of this research has since 
been scrutinised by experts. (4)   
The regulations propose potentially e!ective methods to reduce 
testosterone to below the 5nmol/L limits as oral contraceptives, 
GNRH agonists (akin to those used to treat prostate cancer) and 
even gonadectomy. (8) However, it advocates the use of oral con-
traceptives which “are generally milder and have less signi"cant side 
e!ects”. (7) Combined oral contraceptives reduce both ovarian and 
adrenal endogenous androgen production. (10) It justi"es the ruling 
as risk-acceptable due to the fact testosterone reduction is the clini-
cal standard of care for these 46 XY DSD conditions.
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Mokgadi Caster Semenya became known on the global athletics 
stage at the Berlin World Championships in 2009. But instead of 
being known for her outstanding success of an 800m gold at the age 
of 18, the South African’s achievement soon became overshadowed 
by becoming the unwilling face of the dispute over hyperandrog-
enous female athlete. Her gender began to be scrutinised by the 
world, and Semenya stated that she was facing “relentless public 
scrutiny”. (7,11) The greatest backlash, however, came from her 
fellow competitors: “These kinds of people should not run with us” 
said Italian athlete Elisa Cusma. (12) “Just look at her…” said Rus-
sian "$h place "nisher Mariya Savinova, who ironically later had 
her London 2012 gold removed for illegal doping, whilst Semenya’s 
silver medal was subsequently upgraded. (13,14) 
Figure 2 details a timeline of Semenya’s milestones over the last 
decade; she has been in a battle with the authorities ever since be-
ing questioned about her gender in 2009. Semenya is a cisgender 
woman, a female by law and assigned at birth. Her medical records 
are rightly con"dential, however, there has been signi"cant media 
speculation over what may have caused her to have an ‘androgenous 
physical appearance’. Given that the DSD regulations have been 
applied to her, it has been assumed that she is 46XY with DSD. 
(2,6,7)
One can o$en empathise with Semenya once understanding her 
legal battle against the IAAF over her right to race; almost half of 
her time since its beginning has been spent taking testosterone-sup-
pressing medication. (7) There was no established clinical protocol 
at the time to lower testosterone to <5 nmol/L in an a 46XY DSD 
athlete, therefore Semenya’s treatment has been somewhat experi-
mental. The ASA contended she did not give informed consent 
for the participation in the IAAF research. (7) She su!ered a range 
of side e!ects including weight gain, nausea, fevers and constant 
abdominal pain (some of this would be attributable to withdrawal 
from testosterone), which a!ected her mental and physical com-
mitment to training. (7) Semenya described the treatment she 
received by the IAAF during the gender veri"cation process, 
including intimate clinical examinations at age 18, at the same time 
witnessing the public discussion of her body and private medical 
information, as “atrocious and humiliating”. It should be noted, 
however, that these words were used as part of her legal case which 
claims psychological distress, so are not completely objective. (7) 
On the other side of the case, the IAAF claim that the DSD regula-
tions are “to give female athletes the same opportunities to excel 
and pro"t from the sport as male athletes” claiming they “do not 
involve any judgement on or questioning of an individual’s sex or 
gender identity” (7)
Figure 1 
Summary of the normal physiological pathway of androgen 
synthesis, blue text represents enzymes
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Box 1 
Summary of the current IAAF regulations for eligibility for DSD 
athletes re"ned in 2019. (8) 
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Masculinisation of females can arise from the delivery of ‘male’ 
doses of testosterone (or a synthetic analogue) orally, trans-dermal-
ly, or intramuscularly as demonstrated by the historical example of 
Andreas Krieger (previously European shot-put champion Heidi) 
in the East German doping scandal of the 80s. (6) Testosterone 
is a potent androgen transported  freely in the blood or bound 
to sex hormone binding globulin (SHBG), and contributes to 
the development of male secondary sexual characteristics. (16) 
Its relevant qualities here are derived from its anabolic action on 
skeletal muscle, increase in circulating haemoglobin, and inhibition 
of adipogenesis explaining its exogenous use as a performance-
enhancing drug – it has received extensive press coverage in doping 
scandals. (16) For an outline of the cellular e!ects of testosterone, 
see "gure 3. Masculinisation of females can arise from the deliv-
ery of ‘male’ doses of testosterone (or a synthetic analogue) orally, 
trans-dermally, or intramuscularly as demonstrated by the histori-
cal example of Andreas Krieger (previously European shot-put 
champion Heidi) in the East German doping scandal of the 80s. (6) 
Testosterone is a potent androgen transported  freely in the blood or 
bound to sex hormone binding globulin (SHBG), and contributes 
to the development of male secondary sexual characteristics. (16) 
Its relevant qualities here are derived from its anabolic action on 
skeletal muscle, increase in circulating haemoglobin, and inhibition 
of adipogenesis explaining its exogenous use as a performance-
enhancing drug – it has received extensive press coverage in doping 
scandals. (16) For an outline of the cellular e!ects of testosterone, 
see "gure 3.
A$er the Chand ruling, the main paper released by the IAAF was 
published in the British Journal of Sports Medicine, which we shall 
refer to as BG17. (17) A second paper was published a year later in 
response to criticism (BHKE18), which acknowledged methodo-
logical changes which led to changes in calculated performance 
di!erences compared to BG17. (4,18) The research found that 
based on 21 athletic events, female athletes with higher serum 
free testosterone performed signi"cantly better (p<0.05) in 400m 
(2.73% margin), 400m hurdles (2.78%), 800m (4.53%), hammer 
throw (4.53%) and pole vault (2.94%). (17) Chand’s sprinting dis-
tances did not feature in the testosterone performance-enhancing 
events, hence why the DSD regulations focus on middle distance 
events. Interestingly, of the aforementioned events which did show 
testosterone-related performance di!erences, higher testosterone 
conferred the smallest advantage in Semenya’s event (800m). De-
spite having shown a signi"cant testosterone-related performance 
di!erence in both the hammer throw and pole vault, the IAAF has 
decided to feature neither of these "eld events in their DSD regula-
tions. Semenya commented “it feels like this new rule was created 
because of me”. (7)
This work was conducted by those with a con#ict of interest and 
has been methodologically criticised, with many academics argu-
ing that it is inherently #awed. (19-21) Given its importance, it is 
imperative that this research is held to high bioethical standards, and 
the only way to do this is by the involvement of the scienti"c com-
munity. Professor Roger Pielke Jr. of the University of Colorado 
and director of its sports governance centre, who also acted as an 
Figure 2 
Timeline of key events in Caster Semenya’s running career and 
dealings with the IAAF, adapted from (7,15).
Figure 3 
Schematic diagram detailing the anabolic mechanisms by which 
androgens increase muscle mass. AR = androgen receptor (16).
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expert witness for Semenya in her CAS case against the IAAF, 
responded to a question about the integrity of the research: “We 
wouldn’t want tobacco companies doing research on health e!ects 
of cigarettes. This is the same.” Professor Pielke wrote a thought-
provoking piece for Nature on the topic, explaining how the IAAF 
have violated the principles of the Helsinki declaration in their re-
search process, highlighting the risks of implementing sports policy 
sanctioning ‘unproven interventions’. (22) 
Further, the ‘cut-o!’ testosterone level chosen by the IAAF is arbi-
trary. We have no substantial evidence on the e!ects of testosterone 
suppression in this DSD group as interventional placebo-controlled 
studies aren’t practically or ethically feasible. 5 nmol/L was lowered 
(a$er the original 10 nmol/L before the Chand ruling) based on the 
data from Handelsman e. 2018. (23) which actually used perfor-
mance data from Semenya herself and other athletes who under-
went testosterone suppression before the Chand ruling. The paper 
derived a bimodal distribution of testosterone concentrations in 
healthy men (7.7-29.4 nmol/L) and healthy pre-menopausal wom-
en (0-1.68 nmol/L) and by making an allowance for women with 
PCOS and mild hyperandrogenism, decided the cut-o! should be 
5 nmol/L. Based on healthy subjects from the general population, 
this data may not be directly applicable to elite athletes or those 
with DSD, and these ranges are not consistent with a more recent 
review. (24) It is very di%cult to ascertain an absolute threshold for 
a measurement that displays natural variation in the population, and 
evidence on DSD athletes is extremely limited. However, it is vital 
that the IAAF is completely informed before sanctioning medi-
cal interventions and enforcing bans on athletes in order maintain 
testosterone below an arbitrary level. 
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Success in elite sport is a product of a range of environmental and 
genetic factors, and testosterone is a signi"cant but by no means the 
only in#uence on this. By following the precedent set by the DSD 
regulations, do we need to look at other sports and correct other 
physiological advantages?  It would certainly be ethically contro-
versial to approach a successful swimmer and impose a medical in-
tervention to suppress their elevated haemoglobin. Sport can never 
truly be ‘fair’, it relies on natural and environmental advantages to 
separate those who emerge victorious. If we continue to correct for 
biological advantage, could we eventually homogenise the "eld? 
It is thought provoking to ask: if Semenya hadn’t been so successful 
in her sport, would the new DSD regulations and the controversy 
surrounding the entire issue exist? We may question whether the 
regulations are discriminatory based on appearance: not all females 
get tested so it relies on singling out athletes who have a phenotypi-
cally ‘male’ appearance. One of the reasons these regulations are so 
controversial is the fact
estosterone are seen to have a fair advantage, whereas female ath-
letes’ testosterone-conferring advantage is seen as needing interven-
tion. 
The World Medical Association (a partner organisation to the 
WHO and Global Health Workforce Alliance) displayed ethical 
concerns, stating: “Medical treatment for the sole purpose of alter-
ing the performance in sport is not permissible.” (22) Are the IAAF 
displaying double standards by banning the use of performance-
enhancing drugs whilst condoning the use of performance-dimin-
ishing ones? No treatment comes without side e!ects, and we need 
to weigh up the bene"ts of protecting the female sporting category 
against the risks of physical side e!ects of testosterone withdrawal 
and potential thromboembolic events in the case of oral contracep-
tives, in addition to the psychological distress of subjecting them to 
intimate examinations and gender veri"cation proceedings. (7) It is 
important to remember that running for these women is not only 
a passion, but their means of making a living – the judiciary panels 
owe them a wholly informed decision.
At the core of this debate is what it means to be female. The more 
this is discussed it emerges that this de"nition may not be the same 
in every context. Sex is a combination of genetic, hormonal, psy-
chological and physical components, and what it means to be female 
in sport may be di!erent to what it means in law, or genetics, for 
example. As a society we are discovering that what makes the topic 
of sex and gender so interesting is how it is not binary as tradition-
ally thought. No Y chromosome per se gives you the advantage to 
win a race. Perhaps the Paralympics are ahead of able-bodied sport 
in the way that they allow multiple sub-categories within genders 
and event types, to re#ect the diversity of society.
What is non-negotiable in this debate is that these athletes deserve 
to be treated with sensitivity and respect. We cannot in#uence 
individual cases if we are not professionally involved, but we can 
hold the organisations in charge to the bioethical standards that we 
expect in all medical research and care, to ensure fairness in the 
treatment of future athletes. This is clearly a challenging issue that 
would bene"t from the sporting, legal, and medical communities 
working together to provide the expertise required to reach the 
best possible outcome. No matter what our opinion as healthcare 
professionals, the discussion can bene"t from further input. Amidst 
the controversy, much can be learnt from Semenya’s case: an athlete 
who simply wants to run “free of drugs, free of speculation and free 
of judgement”. (7) 
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